Key result
Estrogen replacement therapy does not change hospitalized heart failure risk in postmenopausal women.
Why the study?
The cardiovascular role and efficacy of estrogen replacement therapy for heart failure among postmenopausal women has been controversial and remains to be further investigated.
Does estrogen replacement therapy reduce the composite endpoint of first hospitalized heart failure and admission to the hospital for heart failure in postmenopausal women?
Meta-Analysis
Yes
Does estrogen replacement therapy reduce the composite endpoint of first hospitalized heart failure and admission to the hospital for heart failure in postmenopausal women?
Answers are grounded in this paper and cite their sources.
Estrogen replacement therapy does not alter heart failure hospitalization risk; confirms neutral effect across randomized trials in postmenopausal women.
BACKGROUND: Based on past epidemiological investigations, the cardiovascular role of estrogen replacement therapy (ERT) in postmenopausal women has always been controversial. The real efficacy of ERT for heart failure (HF) among postmenopausal women remains to be further investigated. This article is based on research into European and American populations. PURPOSE: To determine the impact of estrogen replacement therapy on HF using meta-analysis. METHODS AND MATERIAL: Electronic literature was searched on Web of Science, PubMed, and Embase databases to identify randomized controlled trials (RCTs) comparing the hospitalization for heart failure between ERT users and non-users among postmenopausal women. Pairs of reviewers screened eligible articles independently, extracted data, and evaluated the risk of bias. Summary relative risks were estimated for the composite endpoint of first hospitalized heart failure and admission to the hospital for heart failure. RESULTS: A pooled study of five randomized controlled trials found that estrogen replacement therapy had no significant effect on the composite endpoint in postmenopausal women, with a relative risk of 1.02 (95% CI 0.94-1.10). CONCLUSION: This systematic review demonstrated that estrogen replacement therapy did not significantly change the risk of first hospitalized heart failure and admission to the hospital for heart failure in postmenopausal women.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2024) conducted a meta-analysis in Heart failure. Estrogen replacement therapy vs. Non-users was evaluated on Composite endpoint of first hospitalized heart failure and admission to the hospital for heart failure (RR 1.02, 95% CI 0.94-1.10). Estrogen replacement therapy did not significantly change the risk of first hospitalized heart failure and admission to the hospital for heart failure in postmenopausal women (RR 1.02; 95% CI 0.94-1.10).
Synapse has enriched 10 related papers. Consider them for comparative context: